Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.62 |
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.62 |
| ▸ | ITGA2B known ✓ | P08514 | 1/20 | 0.62 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.62 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.62 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.57 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.55 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.63 |
| ▸ | HPGD | P15428 | 6/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | GGT1 | P19440 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27624365 | 1.00 | HTT (0.75) | HTTKDM4EHPGDHSD17B10ALDH1A1 | |
| SCHEMBL3527 | 0.98 | HTT (0.78) | HTTKDM4EHPGDHSD17B10ALDH1A1 | |
| SCHEMBL29365231 | 0.98 | HTT (0.78) | HTTKDM4EHPGDHSD17B10ALDH1A1 | |
| Bicarbonate SCHEMBL238308 | 0.96 | HTT (0.75) | HTTKDM4EHPGDHSD17B10ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL22437491 | 0.96 | HTT (0.75) | HTTKDM4EHPGDHSD17B10ALDH1A1 | |
| Fluoride SCHEMBL3190250 | 0.96 | HTT (0.75) | HTTKDM4EHPGDHSD17B10ALDH1A1 | |
| Phthalic Acid SCHEMBL8680432 | 0.96 | HTT (0.75) | HTTKDM4EHPGDHSD17B10ALDH1A1 | |
| Bicarbonate SCHEMBL21517635 | 0.96 | HTT (0.75) | HTTKDM4EHPGDHSD17B10ALDH1A1 | |
| SCHEMBL10404879 | 0.96 | HTT (0.75) | HTTKDM4EHPGDHSD17B10ALDH1A1 | |
| Bicarbonate SCHEMBL29943714 | 0.96 | HTT (0.75) | HTTKDM4EHPGDHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104350047-A | Substituted chroman compounds as calcium sensing receptor modulators | LUPIN LTD | 2015-02-11 | — | — | CN | claimed |
| US-8829028-B2 | 5-HT4 receptor antagonists for the treatment of heart failure | SERODUS AS (NO) | 2014-09-09 | — | — | US | claimed |
| US-20090169545-A1 | 5-HT4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF HEART FAILURE | SERODUS AS (NO) | 2009-07-02 | — | — | US | claimed |
| US-20060094715-A1 | 5-Ht4 receptor antagonists for the treatment of heart failure | SERODUS AS (NO) | 2006-05-04 | — | — | US | claimed |
| CN-119371391-A | Aroyl compound and preparation method and application thereof | 河北医科大学 | 2025-01-28 | — | — | CN | disclosed |
| CN-117693511-A | Penicillin binding protein inhibitors | 维纳拓尔斯制药公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-111655681-B | Heterocyclylamino-substituted triazoles as modulators of Rho-related protein kinases | 莱德克斯制药公共有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-9974779-B2 | Piperidine derivatives as human papilloma virus inhibitors | VAXART, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20180021318-A9 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | VAXART, INC. | 2018-01-25 | — | — | US | disclosed |
| EP-2670754-B1 | (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | BOEHRINGER INGELHEIM INT (DE) | 2017-05-24 | — | — | EP | disclosed |
| CN-104350047-B | substituted chroman compounds as calcium sensing receptor modulators | 卢平亚特兰蒂斯控股有限公司 | 2017-05-24 | — | — | CN | disclosed |
| US-20170079968-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | AVIRAGEN THERAPEUTICS INC (US) | 2017-03-23 | — | — | US | disclosed |
| US-5476863-A | Inhibitors of platelet activating factor and diseases caused thereby; stability | EISAI CO., LTD. (JP) | 1995-12-19 | — | — | US | disclosed |
| EP-0353474-B1 | Glycerin derivative and its pharmacological use | EISAI CO LTD (JP) | 1995-04-05 | — | — | EP | disclosed |
| US-5273985-A | A 1-phenylaminocarbonyl-2-sulfoamidophenyleneamino-3-pyrid-2-ylaminocarbonyl glyceride | EISAI CO., LTD. (JP) | 1993-12-28 | — | — | US | disclosed |
| US-5037827-A | Useful for treatment of disease caused by platelet activating factory | EISAI CO., LTD. (JP) | 1991-08-06 | — | — | US | disclosed |
| EP-0353474-A2 | Glycerin derivative and its pharmacological use | Eisai Co., Ltd. (JP) | 1990-02-07 | — | — | EP | disclosed |
| CN-1039414-A | Glycerol derivatives and pharmaceutical use thereof | EISAI CO LTD (JP) | 1990-02-07 | — | — | CN | disclosed |
| US-4720494-A | Anticholinergic eucatropine esters and antiperspirant use thereof | THE GILLETTE COMPANY (US) | 1988-01-19 | — | — | US | disclosed |
| US-4388246-A | THERMAL SPLITTING OF CARBAMATES | BAYER AKTIENGESELLSCHAFT (DE) | 1983-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170079968-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | POLI, VHL, EBNA1BP2 | ESR1 3801/4885ITGB3 4003/4885ITGA2B 4208/4885 |
| US-20180021318-A9 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | POLI, VHL, EBNA1BP2 | ESR1 3801/4885ITGB3 4003/4885ITGA2B 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.